Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + cisplatin + 5-fluorouracil + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
TPF2 (also referred to as TP²F) is an experimental induction therapy regimen combining the standard-of-care TPF chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) with the immune checkpoint inhibitor pembrolizumab. This combination is being evaluated for the treatment of untreated, locally-advanced, unresectable squamous cell head and neck carcinoma (HNSCC). The regimen aims to leverage the cytotoxic effects of chemotherapy to debulk the tumor and potentially enhance the anti-tumor immune response induced by pembrolizumab, which targets the programmed cell death protein 1 (PD-1) receptor. Following induction with TPF2, patients typically proceed to radiotherapy combined with carboplatin.
- Other names
- TPF plus pembrolizumabPICH regimen
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on docetaxel + cisplatin + 5-fluorouracil + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + cisplatin + 5-fluorouracil + pembrolizumab.